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STAT3 is associated with embryo development and survival as well as proliferation andmetastasis of
tumor cells. In a previous study, we demonstrated that STAT3-Interacting Protein As a Repressor
(SIPAR) enhances the dephosphorylation of STAT3 and negatively regulates its activity. However,
it remains unclear how SIPAR inhibits phosphorylation of STAT3. Here we demonstrate that SIPAR
directly interacts with T cell protein tyrosine phosphatase TC45 and enhances its association with
STAT3. This interaction triggers an accelerated dephosphorylation process for STAT3.
Furthermore, SIPAR inhibits the transcriptional activity of STAT3 in wild-type MEF cells but not in
TC45 null MEF cells. These results suggest that SIPAR terminates the activation of STAT3 through
a dephosphorylation process that is dependent upon interaction with TC45 in the nucleus.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
STAT3 is a transcription factor that participates in embryo
development and many cellular processes [1]. Like other members
of the STAT family, STAT3 is tyrosine-phosphorylated by Jaks and
dimerized to translocate into the nucleus to activate target genes
upon stimulations of cytokines and growth factors [2]. Studies
have shown that the constitutive activation of STAT3 is presented
in several cancer cell lines and associated with a number of human
cancers including prostate, breast, lung, brain, and pancreaticcancers [2–7]. In recent publications, numerous groups have
demonstrated that inhibition of STAT3 can suppress growth of can-
cer cells either by promoting apoptosis or by inhibiting cell prolif-
eration [8].
The activity of STAT3 is regulated by both positive and negative
factors in the cytoplasm and nucleus. Among the negative regula-
tors, protein tyrosine phosphatases (PTPs) are apparently critical in
down-regulating the STAT3 activity [9,10]. In particular, it has been
documented that T cell protein tyrosine phosphatase TC-PTP nega-
tively regulates the STAT3 activity either in the cytoplasm, through
dephosphorylating protein tyrosine kinase JAK [11], or in the
nucleus, through directly dephosphorylating STAT3 [10]. Other
protein tyrosine phosphatases, including PTPTN9/Meg2 [12] and
PTPN11/SHP2 [9], also regulate the STAT3 phosphorylation.
However, it remains unclear how these phosphatases speciﬁcally
regulate the STAT3 activity. Recently we demonstrated that an
adaptor protein, GdX/Ubl4A, bridges the interaction of T cell pro-
tein tyrosine phosphatase TC45 with STAT3 and deﬁnes the speci-
ﬁcity of TC45 to recognize phosphorylated STAT3 [13]. Since STAT3
functions under diverse physiological and pathological conditions,
we speculated that more adaptor proteins are required for different
phosphatases to interact with STAT3.
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As a Repressor), also named Acpin1 [14], inhibits the phosphoryla-
tion of STAT3 [15,16]. Our previous observations showed that
SIPAR interacted with STAT3 and suppressed the progression of
melanoma by repressing the expression of STAT3 targeted genes
[16]. However, no speciﬁc phosphatase catalytic domain was pre-
dicted for SIPAR. To reveal the mechanism by which SIPAR regu-
lates the STAT3 activity, in the current study, we performed a
co-immunoprecipitation experiment and identiﬁed that SIPAR
interacted with TC45. Our data demonstrated that SIPAR inhibited
the activity of STAT3 via TC45.
2. Materials and methods
2.1. Plasmids and antibodies
STAT3 related constructs were kept in this lab.
pGL3/(APRE)4-Luc reporter was provided by Dr. Sachiko Ezoe from
Osaka University. TC45 and SIPAR plasmids were constructed in
this lab [13,16]. Human interleukin-6, IL-6 soluble receptor and
the TC-PTP antibody were purchased from R&D Biotechnology.
Anti-STAT3 antibodies (C-20) and anti-Actin antibody (C-2) were
purchased from Santa Cruz Biotechnology. Anti-p-STAT3 antibod-
ies (9131L) were purchased from Cell Signaling Technology.
2.2. Cell culture and transfection
HEK293T, MEFTC45+/+ and MEFTC45/ cells were grown in
DMEM containing 10% fetal bovine serum. B16 cells were grown
in RPMI-1640 containing 10% fetal bovine serum. Lipofectamine
2000 (Invitrogen) was used for transient transfection of
HEK293T, MEFTC45+/+, MEFTC45/ and B16 cells.
2.3. Luciferase assay
Luciferase assays were performed with the indicated plasmids
using pGL3/(APRE)4-luc reporter construct, a luciferase reporter
driven by 4 repeats of the acute phase response elements
(APRE). pRL-TK was used as an internal control. Data were nor-
malized with the internal control. STAT3 luciferase activity was
measured using a luciferase assay system (Promega) and results
were presented as a relative mean with S.D. from triplicate
experiments.
2.4. Immunoprecipitation and dephosphorylation assay
Immunoprecipitation and Western blot experiments were per-
formed according to a previous protocol [17]. The dephosphoryla-
tion assay was performed under starvation conditions according to
our previous report [13].
3. Results
3.1. SIPAR directly interacts with TC45
Our previous study showed that SIPAR interacted with STAT3
[16]. In an analysis of SIPAR interacting proteins, we speculated
that SIPAR might associate with TC45, a phosphatase that regulates
the activity of STAT3 in the nucleus [10]. Therefore, we examined
the interaction of SIPAR and TC45 in mammalian cells. For this pur-
pose, Myc-tagged SIPAR (Myc-SIPAR) and HA-tagged TC45
(HA-TC45) were co-expressed in HEK293T cells for an immunopre-
cipitation experiment with an anti-HA antibody. Western blot
analyses demonstrated that HA-TC45 precipitated down
Myc-SIPAR protein (Fig. 1A), suggesting that SIPAR interacts withTC45 in intact cells. Furthermore, we validated the interaction in
a GST pull down experiment using GST-tagged TC45 protein
(GST-TC45) puriﬁed from Escherichia coli and Myc-SIPAR protein
expressed in HEK293T cells (Fig. 1B). To reveal a direct interaction
of the proteins, we used puriﬁed His-SIPAR and GST-TC45 and per-
formed an in vitro GST-pull down experiment. The results showed
that GST-TC45 strongly pull down His-SIPAR (Fig. 1C), suggesting
that TC45 and SIPAR interact directly in vitro.
To examine whether the endogenous SIPAR protein interacts
with TC45, we used cell lysates from mouse embryos, where
SIPAR is abundantly expressed. An immunoprecipitation experi-
ment demonstrated that antibodies against mouse SIPAR precipi-
tated down the endogenous TC45 protein but IgG failed (Fig. 1D),
suggesting that SIPAR interacts with TC45 under physiological
conditions.
To characterize the domains responsible for the interaction
between SIPAR and TC45, we employed TC45 deletions of either
PTP (protein tyrosine phosphatase) domain or CT (c-terminal)
domain. An immunoprecipitation experiment indicated that only
the region encoding the PTP domain is associated with SIPAR
(Fig. 1E). These analyses indicated that SIPAR interacts with TC45
via the PTP domain of TC45.
To further examine whether TC45 and SIPAR co-localize in
mammalian cells, we performed an immunostaining assay in
MCF7 cells. The results demonstrated that GFP-SIPAR and TC45
co-localized in the nucleus (Fig. 1F). The co-distribution of SIPAR
and TC45 in the nucleus provided a clue that the two proteins, pos-
sibly through their interaction, function in the nucleus.3.2. SIPAR enhances the interaction of STAT3 and TC45
Since SIPAR interacts with both STAT3 and TC45, we questioned
whether SIPAR affects the association of STAT3 with TC45 in mam-
malian cells. To examine the hypothesis, we co-expressed
Flag-STAT3, Myc-SIPAR and HA-TC45 in HEK293T cells. An IP anal-
ysis revealed that HA-TC45 was able to form a complex with
Flag-STAT3 under IL-6 treatment (Fig. 2A, middle lane).
Interestingly, the interaction of HA-TC45 and Flag-STAT3 was
greatly enhanced when Myc-SIPAR was co-expressed in cells trea-
ted with IL-6 (Fig. 2A, last lane). Simultaneously, we observed a
strong interaction of HA-TC45 and Myc-SIPAR (Fig. 2A, second
panel). A quantitative analysis showed that the interaction of
Flag-STAT3 and HA-TC45 in the presence of Myc-SIPAR was
enhanced more than 8-fold in comparison with that in the control
(Fig. 2B). To examine whether the STAT3–SIPAR–TC45 complex
forms in vitro, we used puriﬁed GST-TC45, Flag-STAT3 and
Myc-SIPAR expressed in mammalian cells treated with IL-6 for a
GST pull-down assay. The result indicated that the interaction
between GST-TC45 and Flag-STAT3 was also enhanced in the pres-
ence of Myc-SIPAR (Fig. 2C and D).
To examine whether cytokines enhance the interaction of
endogenous STAT3, SIPAR and TC45 proteins in mammalian cells,
we performed an immunoprecipitation experiment using an anti-
body against TC45. The result showed that the antibody against
TC45 precipitated down endogenous STAT3 and SIPAR in the
presence of IL-6 (Fig. 2E). Furthermore, it appears that the inter-
action of SIPAR with TC45 was equally presented in the absence
or presence of IL-6 (Fig. 2E, the second lane; Fig. 2F). To reveal
whether SIPAR is required for the interaction of TC45 with
STAT3 in the presence of IL-6, we depleted endogenous SIPAR
using an siRNA against SIPAR in B16 cells. The results showed
that depletion of SIPAR abrogated the interaction of TC45 with
STAT3 (Fig. 2G). Taken together, these results suggest that
SIPAR, STAT3 and TC45 form a complex and SIPAR enhances the
interaction of STAT3 with TC45.
Fig. 1. SIPAR interacted with TC45. (A) SIPAR interacts with TC45 in mammalian cells. Myc-SIPAR was co-expressed with HA-tagged TC45 in 293T cells. IP was performed as
indicated. (B) GST pull-down assay. GST and GST-fusion TC45 proteins were puriﬁed with GST beads. Myc-SIPAR was expressed in 293T cells. (C) SIPAR interacts with TC45
in vitro. A GST pull down experiment was performed using puriﬁed GST-45 and His-SIPAR. (D) Endogenous SIPAR interacts with TC45 in mouse embryo. The lysates from a
mouse embryo (days post coitum 11.5) were used for an immunoprecipitation. (E) The PTP domain of TC45 responded to the interaction with SIPAR. An immunoprecipitation
assay was performed with an HA antibody. (F) SIPAR colocalized with TC45 in nucleus.
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As SIPAR interacts with STAT3 dependent on IL-6, we ques-
tioned whether SIPAR associates with p-STAT3, a tyronse phospho-
rylation form. For this purpose, we puriﬁed GST-STAT3 protein
expressed from either mammalian cells under IL-6 stimulation or
E. coli where no phosphorylation occurs. An IP result demonstrated
that GST-STAT3 puriﬁed from mammalian cells strongly precipi-
tated down Myc-SIPAR but GST-STAT3 puriﬁed from E. coli precip-
itated much less Myc-SIPAR in vitro (Fig. 3A). This result suggests
that SIPAR preferably recognizes the phosphorylated STAT3.
To further conﬁrm the phosphorylation of STAT3 is critical for
the interaction with SIPAR, we used a mutant of STAT3,
STAT3(CYF), which could not be phosphorylated at residue Y705,
to perform an IP experiment. The result showed that Myc-SIPAR
precipitated down wild type Flag-STAT3 but no Flag-STAT3(CYF)
(Fig. 3B). Interestingly, we observed that a constitutively activated
mutant, STAT3(CA), which was generated by a mutation of residues
A661 and N663 into cysteine, remained of no interaction with
SIPAR (Fig. 3B, the third lane). This is explainable as we did not
stimulate the cells with IL-6 whereas the STAT3(CA) is a dimerized
form to spontaneously translocate into the nucleus [13]. This result
implies that the interaction of SIPAR with STAT3 dependent on the
phosphorylation status but not on the nuclear localization. A recip-
rocal IP experiment using an anti-Flag antibody conﬁrmed the
result (Fig. 3C).To clarify whether TC45 interacts with phosphorylated STAT3
with the assistance of SIPAR in the nucleus, we separated proteins
from the cytoplasm and nucleus of cells treated with or without
IL-6. An IP experiment using the fragments of the cells indicated
that HA-TC45 interacts strongly with Flag-STAT3 and
over-expression of SIPAR enhanced this interaction in the nucleus
(Fig. 3D), implying that both TC45 and SIPAR prefer to interact with
phosphorylated STAT3. As STAT3 contains SH2 domain which is
important for interaction with TC45, we analyzed which domain
of STAT3 is critical for the interaction with the SIPAR/TC45 com-
plex. For this purpose, we expressed a variety of domains of
STAT3 (Fig. 3E) and performed an IP experiment in the presence
of HA-TC45 and Myc-SIPAR. The results showed that both
Myc-SIPAR and HA-TC45 proteins are presented in the complex
of Flag-STAT3(DB), Flag-STAT3(LD) or Flag-STAT3(SH2), indicating
that SIPAR and TC45 interacts with DB, LD and SH2 domains of
STAT3 (Fig. 3F). This result suggests that SIPAR and TC45 associate
with STAT3 at the region of the DB, LD and SH2 domains.
3.4. SIPAR inhibits the activity of STAT3 through TC45
To reveal the biological function of SIPAR, we examined the
activity of STAT3 at the transcriptional level and its phosphoryla-
tion status. A luciferase reporter linked to a STAT3 binding element
(APRE) was transfected into MEFTC45+/+ and MEFTC45/ cells. The
results showed that over-expression of SIPAR with an adenovirus
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Fig. 2. SIPAR enhances the interaction of STAT3 and TC45. (A) SIPAR mediated the interaction of STAT3 and TC45. IP assay was performed with HEK293T cells. Flag-STAT3,
HA-TC45 and Myc-SIPAR were over-expressed as indicated. (B) A quantitative analysis of the Flag-STAT3 and HA-TC45 complex. (C) SIPAR accelerated the interaction of
STAT3 and TC45. GST pull down assay was performed with puriﬁed GST-TC45 and over-expressed STAT3 and SIPAR in mammal cells as indicated. (D) A quantitative analysis
of the Flag-STAT3 and GST-TC45 complex is shown. (E) IL-6 induces the interaction of STAT3, TC45 and SIPAR in B16 cells. B16 cells were treated with/without IL-6
stimulation. (F) The interaction of SIPAR and TC45 is not regulated by IL-6. (G) Depletion of SIPAR impairs the interaction of TC45 with STAT3 in response to IL-6 stimulation.
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MEFTC45+/+ cells treated with IL-6 (Fig. 4A). However,
over-expression of SIPAR had no signiﬁcant effect on the inhibition
of IL-6 stimulation in MEFTC45/ cells (Fig. 4B). These results show
that SIPAR inhibited the transcription activity of STAT3 mainly
through TC45.
We next examined the level of phosphorylated STAT3
(p-STAT3) under over-expression of SIPAR. A Western blot analysis
from HEK293T cells demonstrated that, while over-expression of
TC45 alone led to decreased p-STAT3, co-expression of SIPAR with
TC45 further decreased the level of p-STAT3 after IL-6 stimulation
(Fig. 4C, last lane), suggesting SIPAR and TC45 reduced the phos-
phorylation of STAT3. A quantitative analysis of this result further
demonstrated the effect of SIPAR and TC45 on the reduced phos-
phorylation of STAT3 (Fig. 4D). These results, together with that
from our previous study [16], implied that SIPAR may promote
the dephosphorylation of STAT3.
To examine whether SIPAR regulates the dephosphorylation of
STAT3 through TC45, we performed a Western blot analysis in
MEFTC45+/+ and MEFTC45/ cells, which were stimulated with IL-6
for 30 min and then subjected to cytokine withdrawal after differ-
ent time periods. The results indicated that p-STAT3 remained at a
high level for up to 120 min after cytokine withdrawal in the pres-
ence of Ad/GFP, but was dramatically decreased in the presence of
Ad/SIPAR in 30 min after withdrawal of the cytokine in MEFTC45+/+
cells (Fig. 4E). However, p-STAT3 remained at high levels in
MEFTC45/ cells at different times upon cytokine withdrawal in
the presence of Ad/GFP or Ad/SIPAR (Fig. 4F), suggesting that the
effect of SIPAR on the dephosphorylation of STAT3 was impaired
when TC45 was depleted. Taken together, these results suggestedthat SIPAR promotes the dephosphorylation of STAT3 through
TC45.
On the other hand, we further questioned whether SIPAR is
reciprocally required for the dephosphorylation of p-STAT3 by
TC45. A luciferase experiment indicated that depletion of SIPAR
impaired, but not completely lost, the effect of over-expressed
TC45 on the inhibition of STAT3 transcriptional activity (Fig. 4G,
comparing the forth group of columns with the second group of
columns). A Western blot analysis on the phosphorylation level
of STAT3 indicated that depletion of SIPAR further facilitated the
phosphorylation of STAT3 based on the depletion of TC45
(Fig. 4H). The results suggest that TC45 may have more adaptors
in coordination of the dephosphorylation of p-STAT3.
In summary, we propose a model that SIPAR recruits TC45 to
dephosphorylate STAT3 (Fig. 5). In the nucleus, SIPAR and
TC45 forms a complex, which recognizes phosphorylated STAT3.
The complex of SIPAR/TC45/p-STAT3 is de-associated after the
dephophorylation of STAT3. In this way, the activity of STAT3 is
negatively regulated by SIPAR.
4. Discussion
STAT3 plays a very important role in cell survival, differentia-
tion and proliferation during the embryo development and differ-
ence diseases. Many tumors are attributed to the constitutive
STAT3 phosphorylation, which can be a consequence of either
increased expression and activation of positive regulators or
decreased activities of negative regulators including phosphatases
[18,19]. To date, several phosphatases have been identiﬁed to
mediate the dephosphorylation of STAT3. We previously reported
Fig. 3. SIPAR interacts with phosphorylated STAT3. (A) SIPAR interacts with STAT3 dependent on the phosphorylation of STAT3. Puriﬁed GST-STAT3 proteins which were
expressed from either mammalian cells (M) or E. coli (E) were used to subject to an in vitro GST-pull down experiment using over-expressed Myc-SIPAR. (B–C) SIPAR failed to
associate with STAT3 mutants. Wild type (WT), a constitutively active (CA) and a Y705 mutant (CYF) of STAT3 were used for performed IP experiments using either an anti-
Myc antibody against SIPAR (B) or an anti-Flag antibody against STAT3 and its mutants (C). (D) SIPAR enhances the interaction of TC45 with STAT3 in the nucleus in response
to IL-6 stimulation. Cells were fractioned as cytoplasm and nuclear sections for the immunoprecipitation experiment using an antibody against HA. A non-speciﬁc band was
indicated as NSS. (E) A diagram to show the domains of STAT3. ND-4H: NH2-terminal and coiled-coil domains, DB: DNA binding domain, LD: linker domain, SH2: Src
homology domain 2, CT: C-terminal. (F) SIPAR and TC45 associate with STAT3 at the DB, LD and SH2 domains.
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dephosphorylation in breast cancer cells [12]. Interestingly we
recently found that GdX, a ubiquitin-like domain containing pro-
tein, speciﬁcally interacted with STAT3 and TC45 to mediate speci-
ﬁc dephosphorylation of STAT3 in colon cancers [13]. In this study,
we revealed that SIPAR, a novel protein that interacts with STAT3
[5,15,16], also mediated the dephosphorylation of STAT3 through
TC45. Our study provided another case that a non-phosphatase
protein can bridge a phosphatase to associate with STAT3 (see
Fig. 5).
It has been reported that other phosphatases also dephosphory-
late STAT3. For example, SHP2 have been reported to dephospho-
rylate STAT3 in the nucleus [10,20]. Therefore it is speculated
that whether SIPAR may associate with other phosphatases. Our
data demonstrated that the inhibitory effect of SIPAR to mediate
STAT3 dephosphorylation slightly decreased in MEFTC45/ cells,
suggesting that: (1) the primary role of SIPAR on STAT3 is depen-
dent upon TC45, and (2) SIPAR may also function in cooperation
with other phosphatases. This will be a direction for the future
study.
It remains unclear how the interaction of SIPAR with STAT3 and
TC45 is regulated as SIPAR has no pY-binding motif. In our study,
we observed that IL-6 enhanced the interaction of SIPAR with
TC45 and STAT3. Our results implied that SIPAR might recognizephosphorylated STAT3. This notion was supported by the analysis
on the interaction of puriﬁed GST-STAT3 and Myc-SIPAR, as
GST-STAT3 expressed from the mammalian cells (with strong
phosphorylation) showed strong interaction with Myc-SIPAR
(Fig. 3A). However, on the other hand, we observed that the inter-
action of SIPAR with TC45 remains constant in the presence or
absence of IL-6 (Fig. 2F), suggesting that SIPAR might form a com-
plex with TC45 before the recognition of p-STAT3. We speculate
that the SIPAR–TC45 complex associates with phosphorylated
STAT3 so that the catalytical domain of phosphatase could catch
up the phosphorylated residue Y705 in STAT3. This process occurs
after the phosphorylated STAT3 protein is translocated into the
nucleus. How SIPAR recognizes the phosphorylated STAT3 proteins
in the nucleus remains to be addressed. Also, it is interesting to
question whether TC45 could be phosphorylated during the
SIPAR, TC45 and p-STAT3 complex formation.
SIPAR was originally identiﬁed by our group from a yeast two
hybrid screen using STAT3 as a bait [5,15]. In human, SIPAR is
localized in chromosome 7p22.1, encoding 259 amino acid.
SIPAR is conserved from mouse (with 260 amino acid) to human
with a low homologous similarity in protein sequences [16]. In
a homology search using NCBI blast algorithm we did not ﬁnd
any homology in other species evolutionarily lower than mouse
(data not shown). To date, no reported was linked to the mutation
Fig. 4. SIPAR represses the transcriptional activity and phosphorylation of STAT3 by recruiting TC45. (A) SIPAR inhibits STAT3 transcriptional activity in MEF cells. Cells were
infected with Ad/SIPAR or Ad/GFP (as a control) 24 h before starvation. After starvation of 12 h, cells were treated with/without IL-6 for 8 h. Results shown are mean ± S.D. of
three independent experiments. (B) SIPAR regulated the transcriptional activity of STAT3 in MEF TC45-null cells. (C) SIPAR and TC45 synergistically dephosphorylate p-STAT3.
293T cells were stimulated by IL-6 for 30 min followed by IL-6 withdrawal for 30 min. (D) The p-STAT3 protein levels were analyzed by a quantitative method. (E) SIPAR
accelerates STAT3 dephosphorylation. IL-6 was added to MEFs for 30 min and then withdrawn for the indicated times as above. (F) SIPAR failed to inhibit STAT3
phosphorylation activity in the absence of TC45. IL-6 was added to MEF TC45-null cells for 30 min and then withdrawn for indicated times. (G) Depletion of SIPAR impaired
the function of TC45 in inhibition of STAT3 activity. (H) Depletion of SIPAR further enhances the phosphorylation of STAT3 based on the depletion of TC45.
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of chromosome 7p22.1 (where SIPAR is located) were associated
with autism [21–23]. Interestingly, inhibition of STAT3 was
reported to oppose the occurrence of maternal immune activation
induced autism [24]. This is very interesting as SIPAR is preferably
expressed in brain tissues [16]. On the other hand, deletion and
translocation in 7p22.1 were observed in myeloid leukemia
[25,26], and STAT3 signaling is widely reported to be constitu-
tively active and has been as a target for treatment of myeloid
leukemia [27]. Those coincidences may imply a correlation of
SIPAR and STAT3 in the regulation of these disease processes. It
will be interesting to further study whether SIPAR is related to
these diseases, in particular whether dysregulation of SIPAR
together with STAT3 is related to the process of these diseases.
A genetically SIPAR knock-out mouse model will be useful toreveal the functions of SIPAR in the physiology and pathological
conditions.
Previously we observed that SIPAR was abundant in the heart,
spleen, brain, lung and muscle in the adult mouse and is highly
expressed in the whole mouse embryo [16]. During the embryo
development, SIPAR is mainly expressed in the nerve system
including brain, eye vesicles and vertebral column in the mouse
[5]. Interestingly, SIPAR, also named as Acpin1, was reported to
be highly expressed in the testis and appeared to function in sper-
matogenesis [14]. However, it was well known that the expression
of STAT3 was ubiquitous in different adult tissues. Therefore the
interaction of SIPAR with STAT3 and TC45 could be an event that
occurs speciﬁcally in these tissues and during embryonic develop-
ment. Indeed, in this study we observed the interaction of endoge-
nous SIPAR with TC45 in the mouse embryo (Fig. 1D). However, the
Fig. 5. A model of termination of STAT3 activity in the nucleus by SIPAR that
interacts with TC45. STAT3 is phosphorylated in the cytoplasm after stimulation by
cytokines. SIPAR interacts with TC45 to form a complex which then associates with
phosphorylated STAT3. The SIPAR–TC45 complex mediates dephosphorylation of p-
STAT3 and terminates its transcriptional activity in the nucleus.
1896 F. Ren et al. / FEBS Letters 589 (2015) 1890–1896speciﬁc biological function that enables SIPAR to mediate the
dephosphorylation of STAT3 by interacting with TC45 during
development and human diseases remains exclusive. Further
experiments are needed to address these questions.
In conclusion, we demonstrated that SIPAR enhances the
dephosphorylation of STAT3 and negatively regulates STAT3 activ-
ity through TC45. The next step should be to study whether SIPAR
suppresses STAT3-mediated cell transformation, and the detailed
mechanisms and functions of TC45 involvement in the regulation
of SIPAR-mediated STAT3 dephosphorylation.
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